Adaptimmune

About:

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.

Top Investors: Hercules Capital, OrbiMed, Wellington Management, F-Prime Capital, Novo Holdings

Description:

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Total Funding Amount:

$500M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Oxford, Oxfordshire, United Kingdom

Founded Date:

2008-01-01

Contact Email:

info(AT)adaptimmune.com

Founders:

Ian Laing, James Noble